Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial
- 4 August 2009
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 65 (4) , 641-647
Abstract
Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months in patients with biliary tract cancers (BTCs). The aim of this study was to evaluate the efficacy and safety of the combination chemotherapy with gemcitabine and oxaliplatin (GEMOX) in patients with BTCs including gall bladder cancer.Keywords
This publication has 15 references indexed in Scilit:
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Chemotherapy with Gemcitabine and Oxaliplatin in Patients with Advanced Biliary Tract Cancer: A Single-Institution ExperienceOncology, 2007
- Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancerBritish Journal of Cancer, 2006
- Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancersAnnals of Oncology, 2006
- CholangiocarcinomaThe Lancet, 2005
- Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR studyAnnals of Oncology, 2004
- 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 HospitalsCancer Research and Treatment, 2004
- Review of gemcitabine in biliary tract carcinomaSeminars in Oncology, 2002
- Biliary Tract CancersNew England Journal of Medicine, 1999